MétaCan
Menu
← Back to cohort

Weekly paclitaxel treatment of patients with progressive platinum resistant epithelial ovarian cancer

2005· article· en· W2305245841 on OpenAlexaff
T. Le, Kelly-Anne Baines, Lisa Rambout, P. Rezaifer, M. Al Hayki, Lisa G. Hopkins, Michael Fung Kee Fung

Bibliographic record

VenueJournal of Clinical Oncology · 2005
Typearticle
Languageen
FieldMedicine
TopicOvarian cancer diagnosis and treatment
Canadian institutionsOttawa Public Health
Fundersnot available
KeywordsMedicinePaclitaxelTaxaneChemotherapyInternal medicineOvarian cancerQuality of life (healthcare)OncologyCancerProgression-free survivalSurgeryGastroenterologyBreast cancer

Abstract

fetched live from OpenAlex

5137 Background: Paclitaxel administered on a weekly basis can have both an anti angioneogenesis and apoptotic inducing effects on cancer cells. We studied the activity of weekly Paclitaxel in patients with recurrent platinum resistant ovarian cancer and its effects on patients’ quality of life. Methods: Retrospective reviews of all patients with recurrent platinum resistant epithelial ovarian cancer treated with intravenous continuous weekly Paclitaxel (80mg/m2 for maximum of 24 weeks) were carried out. Evaluable endpoints were toxicities, response rates, and quality of life measurements. Quality of life was assessed using standard FACT-O questionnaire after the fourth weekly treatment. Median overall and progression free survival were estimated using Kaplan Meier method. Analysis of variance were used to compare mean Quality of Life scores between weekly Paclitaxel and other chemotherapy regimens using the existing institutional quality of life database. Results: Thirty-four patients were identified for review. The median line of chemotherapy administered as weekly Paclitaxel was three. The median platinum and taxane free interval were 7.6 months and 10.4 months respectively. Five patients (15%) reported grade 3 or 4 neurotoxicity or fatigue. The median nadir white blood count, haemoglobin, and platelet were 3.65, 99.50, and 224 during the course of treatment. At a median follow up of 7.3 months, fourteen patients (40%) had died. Twenty patients (61%) had a persistent decrease of their Ca125 by more than fifty percent from baseline value. Complete response was observed in three patients (8.8%) with another 14 patients showing partial response (41.2%) based on radiographic criteria. The median progression free survival was 6.10 months (95% CI: 3.81–8.39) and the median survival was 10.43 months (95% CI: 8.49–12.38) from the start of weekly treatment. Quality of Life assessments showed no significant differences between weekly Paclitaxel, Liposomal Doxorubicin, and Topotecan. Conclusions: Weekly Paclitaxel is a well-tolerated and active regimen in patients with recurrent platinum resistant ovarian cancer. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Bristol-Meyer Squibb

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.002

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.072
GPT teacher head0.435
Teacher spread0.363 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2005
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical Oncology→Same topicOvarian cancer diagnosis and treatment→French-language works237,207→